Reproducible diagnosis of chronic lymphocytic leukemia by flow
cytometry: An European Research Initiative on CLL (ERIC) &
European Society for Clinical Cell Analysis (ESCCA)
Harmonisation project

J 2018

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

RAWSTRON, A.C.; K.A. KREUZER; A. SOOSAPILLA; M. SPACEK; Olga STEHLÍKOVÁ et. al.

Basic information

Original name

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

Authors

RAWSTRON, A.C. (826 United Kingdom of Great Britain and Northern Ireland); K.A. KREUZER (276 Germany); A. SOOSAPILLA (36 Australia); M. SPACEK (203 Czech Republic); Olga STEHLÍKOVÁ (203 Czech Republic, belonging to the institution); P. GAMBELL (36 Australia); N. MCIVER-BROWN (826 United Kingdom of Great Britain and Northern Ireland); N. VILLAMOR (724 Spain); K. PSARRA (300 Greece); M. ARROZ (620 Portugal); R. MILANI (380 Italy); J. DE LA SERNA (724 Spain); M.T. CEDENA (724 Spain); O. JAKSIC (191 Croatia); J. NOMDEDEU (724 Spain); C. MORENO (724 Spain); G.M. RIGOLIN (380 Italy); A. CUNEO (380 Italy); P. JOHANSEN (208 Denmark); H.E. JOHNSEN (208 Denmark); R. ROSENQUIST (752 Sweden); C.U. NIEMANN (208 Denmark); W. KERN (276 Germany); D. WESTERMAN (203 Czech Republic); M. TRNENY (203 Czech Republic); S. MULLIGAN (36 Australia); Michael DOUBEK (203 Czech Republic, belonging to the institution); Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution); P. HILLMEN (840 United States of America); D. OSCIER (826 United Kingdom of Great Britain and Northern Ireland); M. HALLEK (276 Germany); P. GHIA (380 Italy) and E. MONTSERRAT (724 Spain)

Edition

Cytometry Part B ( Clinical cytometry), HOBOKEN, WILEY-BLACKWELL, 2018, 1552-4949

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30109 Pathology

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 2.938

RIV identification code

RIV/00216224:14740/18:00102937

Organization unit

Central European Institute of Technology

DOI

https://doi.org/10.1002/cyto.b.21595

UT WoS

000423805500012

EID Scopus

2-s2.0-85040713479

Keywords in English

chronic lymphocytic leukemia; flow cytometry; diagnosis

Abstract

In the original language

The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. ERIC/ESCCA members classified 14 of 35 potential markers as required or recommended for CLL diagnosis, consensus being defined as >75% and >50% agreement, respectively. An approach to validate required markers using normal peripheral blood was developed. Responses were received from 150 participants with a diagnostic workload >20 CLL cases per week in 23/150 (15%), 5-20 in 82/150 (55%), and <5 cases per week in 45/150 (30%). The consensus for required diagnostic markers included: CD19, CD5, CD20, CD23, Kappa, and Lambda. Recommended markers potentially useful for differential diagnosis were: CD43, CD79b, CD81, CD200, CD10, and ROR1. Reproducible criteria for component reagents were assessed retrospectively in 14,643 cases from 13 different centers and showed >97% concordance with current approaches. A pilot study to validate staining quality was completed in 11 centers. Markers considered as required for the diagnosis of CLL by the participants in this study (CD19, CD5, CD20, CD23, Kappa, and Lambda) are consistent with current diagnostic criteria and practice. Importantly, a reproducible approach to validate and apply these markers in individual laboratories has been identified. Finally, a consensus recommended panel of markers to refine diagnosis in borderline cases (CD43, CD79b, CD81, CD200, CD10, and ROR1) has been defined and will be prospectively evaluated. (c) 2017 International Clinical Cytometry Society

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

NV15-30015A, research and development project

Name: Analýza klonální heterogenity chronické lymfocytární leukemie pomoci sekvenování nové generace genu pro B-buněčný receptor. Národní studie.

Cite

RAWSTRON, A.C.; K.A. KREUZER; A. SOOSAPILLA; M. SPACEK; Olga STEHLÍKOVÁ; P. GAMBELL; N. MCIVER-BROWN; N. VILLAMOR; K. PSARRA; M. ARROZ; R. MILANI; J. DE LA SERNA; M.T. CEDENA; O. JAKSIC; J. NOMDEDEU; C. MORENO; G.M. RIGOLIN; A. CUNEO; P. JOHANSEN; H.E. JOHNSEN; R. ROSENQUIST; C.U. NIEMANN; W. KERN; D. WESTERMAN; M. TRNENY; S. MULLIGAN; Michael DOUBEK; Šárka POSPÍŠILOVÁ; P. HILLMEN; D. OSCIER; M. HALLEK; P. GHIA and E. MONTSERRAT. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry Part B ( Clinical cytometry). HOBOKEN: WILEY-BLACKWELL, 2018, vol. 94, No 1, p. 121-128. ISSN 1552-4949. Available from: https://doi.org/10.1002/cyto.b.21595.

@article{1419884,
   author = {Rawstron, A.C. and Kreuzer, K.A. and Soosapilla, A. and Spacek, M. and Stehlíková, Olga and Gambell, P. and McIverandBrown, N. and Villamor, N. and Psarra, K. and Arroz, M. and Milani, R. and de la Serna, J. and Cedena, M.T. and Jaksic, O. and Nomdedeu, J. and Moreno, C. and Rigolin, G.M. and Cuneo, A. and Johansen, P. and Johnsen, H.E. and Rosenquist, R. and Niemann, C.U. and Kern, W. and Westerman, D. and Trneny, M. and Mulligan, S. and Doubek, Michael and Pospíšilová, Šárka and Hillmen, P. and Oscier, D. and Hallek, M. and Ghia, P. and Montserrat, E.},
   article_location = {HOBOKEN},
   article_number = {1},
   doi = {https://doi.org/10.1002/cyto.b.21595},
   keywords = {chronic lymphocytic leukemia; flow cytometry; diagnosis},
   language = {eng},
   issn = {1552-4949},
   journal = {Cytometry Part B ( Clinical cytometry)},
   title = {Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project},
   url = {https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.b.21595},
   volume = {94},
   year = {2018}
}

TY  - JOUR
ID  - 1419884
AU  - Rawstron, A.C. - Kreuzer, K.A. - Soosapilla, A. - Spacek, M. - Stehlíková, Olga - Gambell, P. - McIver-Brown, N. - Villamor, N. - Psarra, K. - Arroz, M. - Milani, R. - de la Serna, J. - Cedena, M.T. - Jaksic, O. - Nomdedeu, J. - Moreno, C. - Rigolin, G.M. - Cuneo, A. - Johansen, P. - Johnsen, H.E. - Rosenquist, R. - Niemann, C.U. - Kern, W. - Westerman, D. - Trneny, M. - Mulligan, S. - Doubek, Michael - Pospíšilová, Šárka - Hillmen, P. - Oscier, D. - Hallek, M. - Ghia, P. - Montserrat, E.
PY  - 2018
TI  - Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project
JF  - Cytometry Part B ( Clinical cytometry)
VL  - 94
IS  - 1
SP  - 121-128
EP  - 121-128
PB  - WILEY-BLACKWELL
SN  - 15524949
KW  - chronic lymphocytic leukemia
KW  - flow cytometry
KW  - diagnosis
UR  - https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.b.21595
N2  - The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. ERIC/ESCCA members classified 14 of 35 potential markers as required or recommended for CLL diagnosis, consensus being defined as >75% and >50% agreement, respectively. An approach to validate required markers using normal peripheral blood was developed. Responses were received from 150 participants with a diagnostic workload >20 CLL cases per week in 23/150 (15%), 5-20 in 82/150 (55%), and <5 cases per week in 45/150 (30%). The consensus for required diagnostic markers included: CD19, CD5, CD20, CD23, Kappa, and Lambda. Recommended markers potentially useful for differential diagnosis were: CD43, CD79b, CD81, CD200, CD10, and ROR1. Reproducible criteria for component reagents were assessed retrospectively in 14,643 cases from 13 different centers and showed >97% concordance with current approaches. A pilot study to validate staining quality was completed in 11 centers. Markers considered as required for the diagnosis of CLL by the participants in this study (CD19, CD5, CD20, CD23, Kappa, and Lambda) are consistent with current diagnostic criteria and practice. Importantly, a reproducible approach to validate and apply these markers in individual laboratories has been identified. Finally, a consensus recommended panel of markers to refine diagnosis in borderline cases (CD43, CD79b, CD81, CD200, CD10, and ROR1) has been defined and will be prospectively evaluated. (c) 2017 International Clinical Cytometry Society
ER  -

RAWSTRON, A.C.; K.A. KREUZER; A. SOOSAPILLA; M. SPACEK; Olga STEHLÍKOVÁ; P. GAMBELL; N. MCIVER-BROWN; N. VILLAMOR; K. PSARRA; M. ARROZ; R. MILANI; J. DE LA SERNA; M.T. CEDENA; O. JAKSIC; J. NOMDEDEU; C. MORENO; G.M. RIGOLIN; A. CUNEO; P. JOHANSEN; H.E. JOHNSEN; R. ROSENQUIST; C.U. NIEMANN; W. KERN; D. WESTERMAN; M. TRNENY; S. MULLIGAN; Michael DOUBEK; Šárka POSPÍŠILOVÁ; P. HILLMEN; D. OSCIER; M. HALLEK; P. GHIA and E. MONTSERRAT. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) \&{}amp; European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. \textit{Cytometry Part B ( Clinical cytometry)}. HOBOKEN: WILEY-BLACKWELL, 2018, vol.~94, No~1, p.~121-128. ISSN~1552-4949. Available from: https://doi.org/10.1002/cyto.b.21595.

Přehled o publikaci